KR102958419B1 - S1p₁ 수용체와 관련된 병태의 치료 방법 - Google Patents
S1p₁ 수용체와 관련된 병태의 치료 방법Info
- Publication number
- KR102958419B1 KR102958419B1 KR1020217024973A KR20217024973A KR102958419B1 KR 102958419 B1 KR102958419 B1 KR 102958419B1 KR 1020217024973 A KR1020217024973 A KR 1020217024973A KR 20217024973 A KR20217024973 A KR 20217024973A KR 102958419 B1 KR102958419 B1 KR 102958419B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- delete delete
- individual
- hydrate
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789937P | 2019-01-08 | 2019-01-08 | |
| US62/789,937 | 2019-01-08 | ||
| PCT/US2020/012783 WO2020146529A1 (en) | 2019-01-08 | 2020-01-08 | Methods of treating conditions related to the s1p1 receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210113298A KR20210113298A (ko) | 2021-09-15 |
| KR102958419B1 true KR102958419B1 (ko) | 2026-04-28 |
Family
ID=69467760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217024973A Active KR102958419B1 (ko) | 2019-01-08 | 2020-01-08 | S1p₁ 수용체와 관련된 병태의 치료 방법 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220142977A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3908276B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022516662A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102958419B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN113874009A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020206700A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3124701A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL284114A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021008263A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020146529A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2528894A1 (en) | 2010-01-27 | 2012-12-05 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| CA3002540C (en) | 2015-01-06 | 2023-11-07 | Arena Pharmaceuticals, Inc. | Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor |
| JP6838744B2 (ja) | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩 |
| KR20190113955A (ko) | 2017-02-16 | 2019-10-08 | 아레나 파마슈티칼스, 인크. | 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법 |
| CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
| JP7397011B2 (ja) | 2018-06-06 | 2023-12-12 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1p1受容体に関連する状態を治療する方法 |
| ES2951870T3 (es) * | 2018-10-03 | 2023-10-25 | Arena Pharm Inc | Etrasimod para su uso en procedimientos para el tratamiento de la esclerodermia |
| MX2021008263A (es) | 2019-01-08 | 2021-10-13 | Arena Pharm Inc | Métodos de tratamiento de afecciones relacionadas con el receptor s1p1. |
| WO2025177319A2 (en) * | 2024-02-22 | 2025-08-28 | Msn Laboratories Private Limited, R&D Center | Solid state forms of L-Arginine, (3R)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopent[b]indole-3-acetate and processes for preparation thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016112075A1 (en) | 2015-01-06 | 2016-07-14 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104311472B9 (zh) | 2008-07-23 | 2020-03-17 | 艾尼纳制药公司 | 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物 |
| PL2342205T4 (pl) * | 2008-08-27 | 2016-12-30 | Podstawione tricykliczne pochodne kwasowe jako antagoniści receptora S1P1 użyteczni w leczeniu zaburzeń autoimmunologicznych i zapalnych | |
| EP2528894A1 (en) | 2010-01-27 | 2012-12-05 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| UY34054A (es) * | 2011-05-02 | 2012-11-30 | Millennium Pharm Inc | FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7 |
| JP6047203B2 (ja) * | 2015-02-20 | 2016-12-21 | セルセウティックス コーポレイション | 消化管の炎症性疾患の予防および/または治療のための宿主防御タンパク質(hdp)模倣薬 |
| MX2021008263A (es) | 2019-01-08 | 2021-10-13 | Arena Pharm Inc | Métodos de tratamiento de afecciones relacionadas con el receptor s1p1. |
-
2020
- 2020-01-08 MX MX2021008263A patent/MX2021008263A/es unknown
- 2020-01-08 AU AU2020206700A patent/AU2020206700A1/en not_active Abandoned
- 2020-01-08 US US17/421,299 patent/US20220142977A1/en not_active Abandoned
- 2020-01-08 KR KR1020217024973A patent/KR102958419B1/ko active Active
- 2020-01-08 CN CN202080018255.4A patent/CN113874009A/zh active Pending
- 2020-01-08 CA CA3124701A patent/CA3124701A1/en active Pending
- 2020-01-08 EP EP20703633.6A patent/EP3908276B1/en active Active
- 2020-01-08 WO PCT/US2020/012783 patent/WO2020146529A1/en not_active Ceased
- 2020-01-08 JP JP2021539637A patent/JP2022516662A/ja not_active Ceased
- 2020-01-08 CN CN202411067321.3A patent/CN118976023A/zh active Pending
-
2021
- 2021-06-17 IL IL284114A patent/IL284114A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016112075A1 (en) | 2015-01-06 | 2016-07-14 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118976023A (zh) | 2024-11-19 |
| AU2020206700A1 (en) | 2021-07-15 |
| US20220142977A1 (en) | 2022-05-12 |
| WO2020146529A1 (en) | 2020-07-16 |
| CA3124701A1 (en) | 2020-07-16 |
| MX2021008263A (es) | 2021-10-13 |
| KR20210113298A (ko) | 2021-09-15 |
| IL284114A (en) | 2021-08-31 |
| CN113874009A (zh) | 2021-12-31 |
| JP2022516662A (ja) | 2022-03-01 |
| EP3908276B1 (en) | 2025-06-11 |
| EP3908276A1 (en) | 2021-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3908276B1 (en) | Methods of treating conditions related to the s1p1 receptor | |
| KR102824401B1 (ko) | S1p1 수용체와 관련된 병태의 치료 방법 | |
| JP7219732B2 (ja) | S1p1受容体に関連する状態の処置方法 | |
| ES2987794T3 (es) | Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1 | |
| JP2023552828A5 (cg-RX-API-DMAC7.html) | ||
| TWI646960B (zh) | 慢性腎臟病之進展抑制或改善用製劑 | |
| JP2025507156A (ja) | 処置方法 | |
| HK40116740A (en) | Methods of treating conditions related to the s1p1 receptor | |
| HK40063670B (en) | Methods of treating conditions related to the s1p1 receptor | |
| HK40063670A (en) | Methods of treating conditions related to the s1p1 receptor | |
| JP2022550458A (ja) | S1p1受容体に関連する状態を処置する方法 | |
| HK40116488A (en) | Methods of treating conditions related to the s1p1 receptor | |
| KR20200021479A (ko) | 페마피브레이트를 함유하는 의약 | |
| WO2026043678A1 (en) | Bexicaserin for use in a method of treatment of seizure-induced sudden unexpected death in epilepsy | |
| JP2026516050A (ja) | 多発性硬化症を治療するためのbtk阻害剤 | |
| TW202339718A (zh) | 治療方法 | |
| CN120112284A (zh) | 阿达格拉西布固体药物组合物 | |
| EP4054572A1 (en) | Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |